Please login to the form below

Not currently logged in
Email:
Password:

Ontruzant

This page shows the latest Ontruzant news and features for those working in and with pharma, biotech and healthcare.

MSD launches EU’s first biosimilar Herceptin in UK

MSD launches EU’s first biosimilar Herceptin in UK

MSD launches EU’ s first biosimilar Herceptin in UK. Ontruzant is set to be strong competition for Roche’s blockbuster. ... The first biosimilar version of Roche’s blockbuster breast cancer drug Herceptin has been launched in the UK by MSD under

Latest news

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    But Roche’s cancer antibody isn’t its only drug battling for market share - breast cancer blockbuster Herceptin (trastuzmab) also has a biosimilar rival in the form of Samsung Bioepis’Ontruzant,

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    First Herceptin biosimilar cleared in Europe. Ontruzant is approved for all the same indications as Roche’s blockbuster. ... Ontruzant is the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU.

  • CHMP backs maintenance therapy for Tesaro's Zejula CHMP backs maintenance therapy for Tesaro's Zejula

    The CHMP recommended approval of two biosimilars, namely Samsung Bioepis' Ontruzant (trastuzumab) - the first biosimilar of Roche's breast cancer therapy Herceptin to get a positive opinion in the EU - and

  • Archive listing

    Ontruzant is set to be strong competition for Roche’s blockbuster. .

More from news
Approximately 4 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics